Psychedelic Health

The EMA is moving toward mechanism-driven drug approvals in oncology. Could psychedelics follow? psychedelichealth.co.uk/2026/03/19/eur…

A new clinical trial suggests psilocybin-assisted therapy may help people quit smoking more effectively than nicotine patches. 40% of participants receiving psilocybin stopped smoking vs 10% with patches. New article breaking down the results: psychedelichealth.co.uk/2026/03/12/qui…

New RAND research: US public support for psilocybin (23%) mirrors cannabis in the 90s. 🍄 While MDMA/LSD lag at ~10%, support for medical use is high. The "experience gap" is real: 62% of users back legal access vs 23% of the general public. 📊 Read full: psychedelichealth.co.uk/2026/03/04/pub…

The US FDA granted breakthrough therapy designation to luvesilocin for postpartum depression. In Phase 2, a single dose reduced symptoms within 7 days, with 70% in remission at Day 28. @ReunionNeuro plans to begin Phase 3 in 2026. Read full: psychedelichealth.co.uk/2026/03/02/fda…

In a new op-ed for Psychedelic Health, Dr. Jenya Antonova argues that patient experience data, not just trial efficacy, will determine the long term winners in psychedelic medicine. As the field matures, real world outcomes may be the true differentiator. psychedelichealth.co.uk/2026/02/25/op-…

Compass Pathways’ Phase 3 psilocybin trial and Helus Pharma’s DMT study show rapid, lasting improvements in depression, marking key steps toward FDA approval and highlighting the evolving psychedelics landscape. Read full: psychedelichealth.co.uk/2026/02/23/psy… #Psychedelics #MentalHealth

@Drug_Science's Medical Psychedelics Working Group is helping shift UK drug policy through evidence, research and collaboration 🧠📊 From Home Office consultations to MDMA trials with UCL, the focus stays on clinical research and regulatory reform. psychedelichealth.co.uk/2026/02/09/how…

Can psychedelics reshape your worldview? 🧠✨ A new study in npj Mental Health Research shows that "self-transcendent" states and deep awe trigger lasting shifts toward holistic thinking. psychedelichealth.co.uk/2026/02/02/can…

We invited Dr. Shoona Vincent of @MAC_Research to write on closing the gap between psychedelic trials and real world care, covering NHS pressure, staffing, set and setting, patient complexity and evidence limits. Read full: psychedelichealth.co.uk/2026/01/30/psy…

Year-in-review: 2025 saw Big Pharma enter psychedelics with AbbVie’s bretisilocin deal, late-stage wins at Compass, MindMed, Cybin and Beckley Psytech, policy progress in Germany, Czech and Australia, and new research data shaping access and regulation psychedelichealth.co.uk/2025/12/23/202…

Takeaways from PSYCH Symposium 2025, Part 2, looks beyond clinical data to what drives patient access, regulation, service models, investment, and system readiness. The shift is clear, progress now depends less on evidence alone and more on infrastructure. psychedelichealth.co.uk/2025/12/19/key…

📢 Excited to be the key media partner for PSYCH Symposium! 🧠 We're sharing key takeaways from their recent London. Opening remarks by Professor David Nutt (@Drug_Science) Fireside with Guy Goodwin (@Compasspathways) Keynote by Justin Smith-Ruiu psychedelichealth.co.uk/2025/12/15/hav…

Shortwave Life Sciences presents a study that examines psilocybin as a treatment for anorexia. The team develops a buccal film that avoids gut issues and aims to influence multiple neural pathways. Read more: psychedelichealth.co.uk/2025/12/04/sho…

We spoke with @COMPASSPathway CEO Kabir Nath on potentially being the first company to bring a classic psychedelic to market. -Mileposts until reaching the finish line. -Compass' influence in the psych space. -Lessons from Lykos' FDA rejection. psychedelichealth.co.uk/2025/12/02/com…

PSYCH Symposium London 2025 will bring researchers, clinicians, policymakers and industry together to discuss developments in psychedelic medicine, including psilocybin for opioid dependence and early anorexia studies. Dec 4 at Conway Hall. psychedelichealth.co.uk/2025/11/21/psy…

🧠 New research in The Journal of Neuroscience shows DMT disrupts long-range brain activity, linking reduced neural structure to ego-dissolution. Participants reporting strongest self-loss showed largest signal changes. psychedelichealth.co.uk/2025/11/26/can…

🧠 New op-ed on Psychedelic Health: “Designing Safety: Why Trauma-informed Models Must Lead the Psychedelic Renaissance.” As psychedelics enter mainstream care, trauma-aware frameworks are key to ethical, effective therapy, by Lucy da Silva. 🔗 psychedelichealth.co.uk/2025/11/10/des…

🎬 In Waves and War hits Netflix, spotlighting ibogaine therapy and featuring Ambio Life Sciences’ clinic. At the same time, Ambio launches Europe’s first physician-led ibogaine facility in Malta 🇲🇹, expanding safe, medically supervised psychedelic care. psychedelichealth.co.uk/2025/11/07/new…

Psilocybin shows promise for OCD, with studies reporting rapid symptom reductions in treatment-resistant patients and animal models. Companies like Ceruvia, Filament, MycoMedica & Compass are now developing psilocybin therapies. psychedelichealth.co.uk/2025/10/30/psi… #ocd #psychedelics

🚨 The FDA has granted Breakthrough Therapy Designation a 5-MeO-DMT compound by Beckley Psytech & Atai Life Sciences, for treatment-resistant depression. A first for this compound, also known as toad venom. psychedelichealth.co.uk/2025/10/22/fda… #Psychedelics #MentalHealth #5MeODMT